ApoGlyx

ApoGlyx is a Swedish biotechnology company founded in 2015 that develops first-in-class therapies using aquaporin inhibitors to treat severe inflammatory diseases like acute pancreatitis and type-2 diabetes. The firm leverages proprietary technology targeting protein channels involved in fluid balance, cancer, malaria, and autoimmunity to create innovative treatments aimed at improving patient quality of life globally.

• Products: RG210179 is a patented first-in-class Aquaporin-9 inhibitor specifically designed for the treatment of acute pancreatitis.
• Services: The company offers research collaborations with academic groups in Italy, France, and Sweden to elucidate aquaporin-9 functions in sepsis and non-alcoholic fatty liver disease.
• Innovation: ApoGlyx utilizes small molecule inhibitors discovered through high-throughput screening assays that demonstrate blood glucose lowering effects and protection from organ damage in murine models.

The organization relies on a scientific advisory board comprising experts from the European Medicines Agency to ensure rigorous development standards for its therapeutic pipeline.